Company Filing History:
Years Active: 2016-2025
Title: Kun Se Lee: Innovator in Vaccine Development
Introduction
Kun Se Lee is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of vaccine development, particularly through his innovative work with cell lines. With a total of 2 patents, his research focuses on improving methods for vaccine production.
Latest Patents
Lee's latest patents include the development of a Vero cell line that can be suspension-cultured in serum-free medium. This innovation, known as sVERO 7C2, is derived from the African Green Monkey Kidney Cell Line and allows for serum-free culture, which is crucial for vaccine production. Additionally, he has patented a method for preparing viruses for vaccines using this novel cell line. Another significant patent involves a Madin-Darby canine kidney (MDCK)-derived cell line that is also adapted to serum-free and suspension culture. This cell line is designed to have low or no tumorigenicity, making it suitable for vaccine production.
Career Highlights
Throughout his career, Kun Se Lee has worked with notable companies such as SK Chemicals Co., Ltd. and SK Bioscience Co., Ltd. His work in these organizations has been instrumental in advancing vaccine technology and improving public health outcomes.
Collaborations
Lee has collaborated with esteemed colleagues, including Yong Wook Park and Bong-Yong Lee. These partnerships have fostered innovation and contributed to the success of his research endeavors.
Conclusion
Kun Se Lee's contributions to vaccine development through his innovative patents and collaborations highlight his importance in the field. His work continues to pave the way for advancements in vaccine technology, ultimately benefiting global health.